Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days for obtaining the report for the FLT3 D835 Point Mutation Analysis Test is 10 business days.

What are the prerequisites for the test FLT3 D835 Point Mutation Analysis Test

  • Specimen: Formalin-fixed, paraffin-embedded tissue block or 10 unstained slides with at least 5 microns of tumor tissue
  • Specimen Preparation: Fill out the Molecular Oncology Test Request Form and include it with the specimen
  • Turnaround Time: 7-10 days
  • Cost: Contact laboratory for pricing information

What are the measure values for the test FLT3 D835 Point Mutation Analysis Test

  • Positive: FLT3 D835 point mutation detected
  • Negative: No FLT3 D835 point mutation detected

What does this test FLT3 D835 Point Mutation Analysis Test identify?

FLT3 D835 Point Mutation Analysis Test

The FLT3 D835 Point Mutation Analysis Test is used to identify a specific mutation in the FLT3 gene known as D835. This mutation is commonly found in patients with acute myeloid leukemia (AML). The test detects the presence of this mutation in the FLT3 gene, which can help guide treatment decisions and prognosis for patients with AML.

Why is this test FLT3 D835 Point Mutation Analysis Test taken?

FLT3 D835 Point Mutation Analysis Test

The FLT3 D835 Point Mutation Analysis Test is taken to detect mutations in the FLT3 gene, specifically at the D835 point. Mutations in the FLT3 gene, especially the D835 point mutation, are commonly found in patients with acute myeloid leukemia (AML). These mutations can impact the prognosis and treatment options for AML patients.

By performing this test, healthcare providers can determine if a patient with AML has a FLT3 D835 mutation, which can help guide treatment decisions and predict the patient's response to certain therapies. This test is crucial for personalized medicine in AML patients and can improve outcomes by tailoring treatment strategies based on the genetic profile of the cancer.

No FAQs available.

Customer Google Rating